<DOC>
	<DOCNO>NCT03010527</DOCNO>
	<brief_summary>This multicenter extension study ass long-term safety , tolerability efficacy bimekizumab adult subject moderate severe chronic plaque psoriasis</brief_summary>
	<brief_title>Study Evaluate Long-term Safety , Tolerability Efficacy Bimekizumab Patients With Chronic Plaque Psoriasis .</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Subject provide informed consent Subject complete dose requirement feeder study complete PS0010 study without meet withdrawal criterion Female subject childbearing potential male subject partner childbearing potential must continue use acceptable method contraception ( detailed PS0010 ) 20 week last dose study treatment PS0011 Subject previously participate study . Female subject plan become pregnant study within 20 week follow last dose study medication . Male subject plan partner pregnancy study within 20 week follow last dose Subject medical psychiatric condition , opinion Investigator , could jeopardize would compromise subject 's ability participate study . Subject must negative interferon gamma release assay ( IGRA ) measure Week 8 PS0010</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chronic plaque psoriasis</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Bimekizumab</keyword>
</DOC>